arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Aardvark Therapeutics, Inc.

AARD Health Care Biotechnology: Pharmaceutical Preparations
$1.39
▼ -68.5% Today
as of Oct 23, 16:45 ET
Last 30 days -74.95% Sep 14 → Oct 23
$1.04 $2.31 $3.57 $4.83 $6.10 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$4.27
High
$4.31
Low
$3.89
Volume
$757,670
Avg Vol
$224,718
Mkt Cap
$115M
P/E (TTM)
—
Beta
—
52w High
$16.60
52w Low
$3.35
Div Yield
—
Shares Out
$22M

Recent Press Releases & News last 60 days · 6 items

Oct 22 · 20:05 PR GlobeNewswire
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data
Oct 21 · 15:00 Zacks
All You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to Buy
Oct 8 · 12:00 PR GlobeNewswire
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
▸ Show all 6 press releases & news Free account →

AARD earnings at a glance

The options market is pricing a move of about ±94.9% after the report, a range of roughly $0.07 to $2.71 from today's $1.39. Over its last 2 reports the stock rose the next day 0 times and fell 2, moving ±9.4% on average; after the most recent report on May 7, 2026 it moved -4.9%. That means options currently expect more movement than AARD has typically delivered. AARD beat the consensus EPS estimate in 1 of its last 4 reported quarters. Implied volatility is currently 6%. The share price of $1.39 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$3.35
$17
0% of range
Avg surprise (last 4)
-10.5%
Avg reaction (last 2)
-9.4%
0% positive
Latest IV / EM
568%
EM ±94.9% · $5 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.37$-1.16$-0.95$-0.73$-0.52 Actual $-0.55Actual $-1.37Actual $-1.05Actual $-0.71Est $-0.70Actual $-0.66Est $-0.52Actual $-0.75Est $-0.82Actual $-0.99Est $-0.81Actual $-0.66 MarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-22M$-17M$-13M$-9M$-4M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.66 — — — — financials
Thu May 7, 2026Mar/2026 $-0.99 $-0.81 -22.2% -39.4% -4.9% earnings
Thu Nov 13, 2025Sep/2025 $-0.75 $-0.82 +8.5% — — earnings
Wed Aug 13, 2025Jun/2025 $-0.66 $-0.52 -26.9% — — earnings
Wed May 14, 2025Mar/2025 $-0.71 $-0.70 -1.4% — -13.8% earnings
Mon Sep 30, 2024Sep 2024 $-1.05 — — — — financials
Sun Jun 30, 2024Jun 2024 $-1.37 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.55 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue—$0———$0——
Cost of revenue————————
Gross profit————————
Operating income$-15M$-22M—$-18M$-16M$-10M—$-5M
Net income$-14M$-22M—$-16M$-14M$-9M—$-4M
EPS (diluted)$-0.66$-0.99—$-0.75$-0.66$-0.71—$-1.05

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$74M$62M$47M$39M$26M$27M$62M—
Inventory————————
Total current assets$81M$94M$112M$129M$145M$155M$74M—
Total assets$81M$99M$117M$133M$147M$157M$78M—
Long-term debt————————
Total liabilities$7M$12M$11M$11M$11M$6M$5M—
Total equity$75M$87M$107M$122M$137M$151M$-55M$-46M

Implied volatility — last 90 days

29%591%1152%1714%2275% Jun 07 — IV 29% · EM ±4.1%Jun 08 — IV 1055% · EM ±139.3%Jun 09 — IV 1115% · EM ±139.7%Jun 10 — IV 36% · EM ±4.3%Jun 16 — IV 2276% · EM ±134.4%Jun 22 — IV 593% · EM ±123.8%Jun 23 — IV 612% · EM ±125.3%Jun 24 — IV 526% · EM ±105.3%Jun 25 — IV 526% · EM ±103.0%Jul 06 — IV 356% · EM ±49.2%Jul 09 — IV 576% · EM ±68.0%Jul 10 — IV 384% · EM ±42.5%Jul 13 — IV 1023% · EM ±85.4%Jul 14 — IV 640% · EM ±46.3%Jul 16 — IV 57% · EM ±2.4%Jul 20 — IV 144% · EM ±34.1%Jul 22 — IV 290% · EM ±66.4%Jul 23 — IV 351% · EM ±79.0%Jul 24 — IV 227% · EM ±50.2%Jul 27 — IV 122% · EM ±25.4%Jul 28 — IV 274% · EM ±56.1%Jul 29 — IV 436% · EM ±87.2%Jul 30 — IV 325% · EM ±63.7%Jul 31 — IV 439% · EM ±84.1%Aug 03 — IV 353% · EM ±62.5%Aug 04 — IV 478% · EM ±82.3%Aug 05 — IV 404% · EM ±67.5%Aug 06 — IV 447% · EM ±72.3%Aug 07 — IV 435% · EM ±68.0%Aug 10 — IV 468% · EM ±64.8%Aug 11 — IV 500% · EM ±66.1%Aug 12 — IV 109% · EM ±13.7%Aug 13 — IV 374% · EM ±44.2%Aug 14 — IV 152% · EM ±16.8%Aug 17 — IV 80% · EM ±6.7%Aug 19 — IV 38% · EM ±2.2%Aug 20 — IV 52% · EM ±2.2%Aug 24 — IV 348% · EM ±72.7%Aug 25 — IV 222% · EM ±45.5%Aug 26 — IV 367% · EM ±73.4%Sep 09 — IV 811% · EM ±101.6%Sep 10 — IV 906% · EM ±107.1%Sep 23 — IV 449% · EM ±89.9%Sep 30 — IV 568% · EM ±94.9%

Sector peers

LIXT
Lixte Biotechnology Holdings, Inc.
$115M $7.21+75.8%
GNLX
Genelux Corporation
$114M $2.00-3.4%
CRBP
Corbus Pharmaceuticals Holdings, Inc.
$123M $4.05-5.5%
ZSTK
ZeroStack Corp.
$104M $3.28-8.1%
SPRB
Spruce Biosciences, Inc.
$129M $45.15+5.7%
MIST
Milestone Pharmaceuticals Inc.
$102M $0.65-6.7%

AARD earnings FAQ

What is AARD's expected move for earnings?

Options currently price a move of about ±94.9%, or $1.32 per share either way from $1.39.

How does AARD stock usually react to earnings?

Across the last 2 reports the average next-day move was ±9.4%, up 0 times and down 2 times.

What is AARD's implied volatility?

AARD's at-the-money implied volatility is about 6% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in